{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:21:10Z","timestamp":1777731670269,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejso.2021.04.041","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T08:20:43Z","timestamp":1621326043000},"page":"1928-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-5059","authenticated-orcid":false,"given":"Robert-Jan","family":"Schipper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri C.","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanne G.","family":"Bloemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne E.","family":"Van Riet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit E.P.","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-7367","authenticated-orcid":false,"given":"Maurice J.C.","family":"van der Sangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-5513","authenticated-orcid":false,"given":"Grard A.P.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2021.04.041_bib1","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1245\/s10434-019-07511-8","article-title":"The changing role of gene-expression profiling in the era of de-escalating adjuvant chemotherapy in early-stage breast cancer","volume":"26","author":"van Steenhoven","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib2","author":"Kalinsky","year":"2020","journal-title":"SABCS"},{"key":"10.1016\/j.ejso.2021.04.041_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000495742","article-title":"Use and impact of the 21-gene recurrence score in relation to the clinical risk of developing metastases in early breast cancer patients in The Netherlands","volume":"21","author":"Schreuder","year":"2018","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.ejso.2021.04.041_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2021.04.041_bib5","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","article-title":"Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach","volume":"26","author":"Weiss","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib6","first-page":"22","article-title":"Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines","author":"Madigan","year":"2020","journal-title":"Breast Canc Res"},{"key":"10.1016\/j.ejso.2021.04.041_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2021.04.041_bib9","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","article-title":"Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure","volume":"25","author":"van der Noordaa","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib11","first-page":"399","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.ejso.2021.04.041_bib12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","article-title":"Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy","volume":"271","author":"Samiei","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2021.04.041_bib13","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-017-5898-z","article-title":"Standard pathologic features can Be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy","volume":"24","author":"Petruolo","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib14","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib15","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1245\/s10434-020-08905-9","article-title":"Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis","volume":"27","author":"Stafford","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib16","series-title":"Dutch breast cancer guideline","year":"2020"},{"key":"10.1016\/j.ejso.2021.04.041_bib17","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1245\/s10434-020-08888-7","article-title":"How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery?","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.2407","article-title":"Refinement of breast cancer classification by molecular characterization of histological special types","volume":"216","author":"Weigelt","year":"2008","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ejso.2021.04.041_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-017-4220-x","article-title":"Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors","volume":"164","author":"Truin","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejso.2021.04.041_bib20","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1245\/s10434-019-07564-9","article-title":"Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma","volume":"26","author":"Thornton","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib21","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1002\/cncr.33104","article-title":"Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer","volume":"126","author":"Christgen","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2021.04.041_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/tbj.12445","article-title":"Is there a role for oncotype dx testing in invasive lobular carcinoma?","volume":"21","author":"Conlon","year":"2015","journal-title":"Breast J"},{"key":"10.1016\/j.ejso.2021.04.041_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19291","article-title":"Molecular profiles and treatment recommendations for invasive lobular carcinoma in a real-world prospective breast cancer registry","volume":"38","author":"Lesnikoski","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS600","volume":"37","author":"Mamounas","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2021.04.041_bib26","first-page":"6","article-title":"Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","author":"Kantor","year":"2020","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.ejso.2021.04.041_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ejso.2021.04.041_bib28","article-title":"Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review","author":"Schipper","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejso.2021.04.041_bib29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","article-title":"Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis","volume":"273","author":"Samiei","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2021.04.041_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-GS1-10","article-title":"Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial","volume":"81","author":"Simons","year":"2021","journal-title":"Canc Res"},{"key":"10.1016\/j.ejso.2021.04.041_bib31","author":"Smidt"},{"key":"10.1016\/j.ejso.2021.04.041_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(19)30334-1","article-title":"Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Saura","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib34","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.041_bib35","author":"Kroep"},{"key":"10.1016\/j.ejso.2021.04.041_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:39:37Z","timestamp":1760060377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321004741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0748798321004741"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.041","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}